LEO Pharma Enters into Rare Skin Diseases with US$760 M Deal with PellePharm
By Sharath Chandra Nakka & Michelle Liu
Pharma Deals Review: Vol 2018 Issue 11 (Table of Contents)
Published: 30 Nov-2018
DOI: 10.3833/pdr.v2018.i11.2375 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
In the latest of its deals focusing on strengthening its dermatology portfolio, LEO Pharma has in-licensed PellePharm’s patidegib, an orphan drug currently under development for the prevention and treatment of Gorlin Syndrome, also known as nevoid basal cell carcinoma (BCC) syndrome...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS